General Information of the Protein
Protein ID
PT01657
Protein Name
Caspase-1
Secondarily
Protein Name
Interleukin-1 beta convertase
Interleukin-1 beta-converting enzyme
p45
Gene Name
CASP1
Secondarily
Gene Name
IL1BC
IL1BCE
Sequence
MADKVLKEKRKLFIRSMGEGTINGLLDELLQTRVLNKEEMEKVKRENATVMDKTRALIDSVIPKGAQACQICITYICEEDSYLAGTLGLSADQTSGNYLNMQDSQGVLSSFPAPQAVQDNPAMPTSSGSEGNVKLCSLEEAQRIWKQKSAEIYPIMDKSSRTRLALIICNEEFDSIPRRTGAEVDITGMTMLLQNLGYSVDVKKNLTASDMTTELEAFAHRPEHKTSDSTFLVFMSHGIREGICGKKHSEQVPDILQLNAIFNMLNTKNCPSLKDKPKVIIIQACRGDSPGVVWFKDSVGVSGNLSLPTTEEFEDDAIKKAHIEKDFIAFCSSTPDNVSWRHPTMGSVFIGRLIEHMQEYACSCDVEEIFRKVRFSFEQPDGRAQMPTTERVTLTRCFYLFPGH
    Show/Hide
Organism
Homo sapiens, Human
Protein Classification
Enzyme
>
Protease
>
Cysteine protease
>
Cysteine protease CD clan
>
Cysteine protease C14 family
Function
Thiol protease involved in a variety of inflammatory processes by proteolytically cleaving other proteins, such as the precursors of the inflammatory cytokines interleukin-1 beta (IL1B) and interleukin 18 (IL18) as well as the pyroptosis inducer Gasdermin-D (GSDMD), into active mature peptides (PubMed:15326478, PubMed:1574116, PubMed:7876192, PubMed:15498465, PubMed:26375003, PubMed:32051255). Plays a key role in cell immunity as an inflammatory response initiator: once activated through formation of an inflammasome complex, it initiates a pro-inflammatory response through the cleavage of the two inflammatory cytokines IL1B and IL18, releasing the mature cytokines which are involved in a variety of inflammatory processes (PubMed:1574116, PubMed:7876192, PubMed:15498465, PubMed:15326478, PubMed:32051255). Cleaves a tetrapeptide after an Asp residue at position P1 (PubMed:1574116, PubMed:7876192, PubMed:15498465). Also initiates pyroptosis, a programmed lytic cell death pathway, through cleavage of GSDMD (PubMed:26375003). In contrast to cleavage of interleukins IL1B and IL1B, recognition and cleavage of GSDMD is not strictly dependent on the consensus cleavage site but depends on an exosite interface on CASP1 that recognizes and binds the Gasdermin-D, C-terminal (GSDMD-CT) part (PubMed:32051255, PubMed:32109412, PubMed:32553275). Cleaves and activates CASP7 in response to bacterial infection, promoting plasma membrane repair (PubMed:22464733). Upon inflammasome activation, during DNA virus infection but not RNA virus challenge, controls antiviral immunity through the cleavage of CGAS, rendering it inactive (PubMed:28314590). In apoptotic cells, cleaves SPHK2 which is released from cells and remains enzymatically active extracellularly (PubMed:20197547).
    Show/Hide
Uniprot ID
Primary ID:
P29466

Secondarily ID:
B5MDZ1
Q53EY6
Q6DMQ1
Q6GSS3
Q6PI75
Q9UCN3
    Show/Hide
Ensembl ID
ENSG00000137752
HGNC ID
HGNC:1499
Subcellular Location
Cytoplasm
Cell membrane
Map of Molecular Bioactivity Related to the Protein
Map of Molecular Bioactivity Related to the Protein

Protein
Cell Line
Compound

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Protein
Cell Line ID: CL000040 , THP-1
Compound ID Compound Name Compound Formula
CP0488915
N-[3-[1-[[(3S)-2-hydroxy-5-oxooxolan-3-yl]carbamoyl]cyclopropyl]-2,4-dioxo-1-propan-2-ylpyrimidin-5-yl]-4-(naphthalen-2-ylamino)benzamide
   Show/Hide
C32H31N5O7
 1
1
IC50 = 23 nM
   TI
   LI
   LO
   TS
CP0315764
N-[3-[1-[[(3S)-2-hydroxy-5-oxooxolan-3-yl]carbamoyl]cyclopropyl]-2,4-dioxo-1-propan-2-ylpyrimidin-5-yl]-4-(quinoxalin-2-ylamino)benzamide
   Show/Hide
C30H29N7O7
 1
1
IC50 = 27 nM
   TI
   LI
   LO
   TS
CP0127391
N-[3-[1-[[(3S)-2-hydroxy-5-oxooxolan-3-yl]carbamoyl]cyclopropyl]-2,4-dioxo-1-propan-2-ylpyrimidin-5-yl]-2-methyl-4-(naphthalen-2-ylamino)benzamide
   Show/Hide
C33H33N5O7
 1
1
IC50 = 38 nM
   TI
   LI
   LO
   TS
CP0111100
N-[3-[1-[[(3S)-2-hydroxy-5-oxooxolan-3-yl]amino]-1-oxopropan-2-yl]-1-methyl-2,4-dioxopyrimidin-5-yl]-4-(quinoxalin-2-ylamino)benzamide
   Show/Hide
C27H25N7O7
 1
1
IC50 = 48 nM
   TI
   LI
   LO
   TS
CP0671637
N-(3-(1-(((3S)-2-Hydroxy-5-oxotetrahydrofuran-3-yl)amino)-1-oxopropan-2-yl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-4-(quinoxalin-2-ylamino)benzamide
   Show/Hide
C29H29N7O7
 1
1
IC50 = 50 nM
   TI
   LI
   LO
   TS
CP0446401
N-[3-[2-[[(3S)-2-hydroxy-5-oxooxolan-3-yl]amino]-2-oxoethyl]-2,4-dioxo-1-propan-2-ylpyrimidin-5-yl]-4-(quinoxalin-2-ylamino)benzamide
   Show/Hide
C28H27N7O7
 1
1
IC50 = 53 nM
   TI
   LI
   LO
   TS
CP0572494
N-[3-[2-[[(3S)-2-hydroxy-5-oxooxolan-3-yl]amino]-2-oxoethyl]-2,4-dioxo-1-propan-2-ylpyrimidin-5-yl]-2-methyl-4-(naphthalen-2-ylamino)benzamide
   Show/Hide
C31H31N5O7
 1
1
IC50 = 66 nM
   TI
   LI
   LO
   TS
CP0488913
N-[3-[1-[[(3S)-2-hydroxy-5-oxooxolan-3-yl]amino]-1-oxobutan-2-yl]-2,4-dioxo-1-propan-2-ylpyrimidin-5-yl]-2-methyl-4-(naphthalen-2-ylamino)benzamide
   Show/Hide
C33H35N5O7
 1
1
IC50 = 76 nM
   TI
   LI
   LO
   TS
CP0451099
N-[3-[2-[[(3S)-2-hydroxy-5-oxooxolan-3-yl]amino]-2-oxoethyl]-2,4-dioxo-1-propan-2-ylpyrimidin-5-yl]-4-(naphthalen-2-ylamino)benzamide
   Show/Hide
C30H29N5O7
 1
1
IC50 = 140 nM
   TI
   LI
   LO
   TS
CP0488914
N-[3-[1-[[(3S)-2-hydroxy-5-oxooxolan-3-yl]amino]-1-oxobutan-2-yl]-2,4-dioxo-1-propan-2-ylpyrimidin-5-yl]-3-methyl-5-(naphthalen-2-ylamino)pyridine-2-carboxamide
   Show/Hide
C32H34N6O7
 1
1
IC50 = 200 nM
   TI
   LI
   LO
   TS
CP0394749
N-[3-[1-[[(4R)-2-hydroxy-6-oxooxan-4-yl]amino]-1-oxobutan-2-yl]-2,4-dioxo-1-propan-2-ylpyrimidin-5-yl]-2-methyl-4-(naphthalen-2-ylamino)benzamide
   Show/Hide
C34H37N5O7
 1
1
IC50 = 210 nM
   TI
   LI
   LO
   TS
CP0562610
N-[3-[1-[[(4R)-2-hydroxy-6-oxooxan-4-yl]carbamoyl]cyclopropyl]-2,4-dioxo-1-propan-2-ylpyrimidin-5-yl]-2-methyl-4-(naphthalen-2-ylamino)benzamide
   Show/Hide
C34H35N5O7
 1
1
IC50 = 360 nM
   TI
   LI
   LO
   TS
Biochemical Assays
Compound ID Compound Name Compound Formula
CP0226547
(S)-3-((1S,9S)-9-(isoquinoline-1-carboxamido)-6,10-dioxooctahydro-1H-pyridazino[1,2-a][1,2]diazepine-1-carboxamido)-4-oxobutanoic acid
   Show/Hide
C24H25N5O7
 4
1 IC50 = 1.3 nM
2 IC50 = 3.4 nM
3 IC50 = 4 nM
4 Ki = 0.6 nM
CP0174148
(1S,10S)-9-[(Isoquinoline-1-carbonyl)-amino]-6,10-dioxo-octahydro-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid ((S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide
   Show/Hide
C26H29N5O7
 2
1 IC50 = 2 nM
2 IC50 = 3.6 nM
CP0446401
N-[3-[2-[[(3S)-2-hydroxy-5-oxooxolan-3-yl]amino]-2-oxoethyl]-2,4-dioxo-1-propan-2-ylpyrimidin-5-yl]-4-(quinoxalin-2-ylamino)benzamide
   Show/Hide
C28H27N7O7
 1
1 IC50 = 3 nM
CP0315764
N-[3-[1-[[(3S)-2-hydroxy-5-oxooxolan-3-yl]carbamoyl]cyclopropyl]-2,4-dioxo-1-propan-2-ylpyrimidin-5-yl]-4-(quinoxalin-2-ylamino)benzamide
   Show/Hide
C30H29N7O7
 1
1 IC50 = 4.7 nM
CP0671637
N-(3-(1-(((3S)-2-Hydroxy-5-oxotetrahydrofuran-3-yl)amino)-1-oxopropan-2-yl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-4-(quinoxalin-2-ylamino)benzamide
   Show/Hide
C29H29N7O7
 1
1 IC50 = 5.6 nM
CP0270369
(3S)-3-[(2S)-2-[(2S)-2-[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanamido]-3-methylbutanamido]propanamido]-4-oxobutanoic acid
   Show/Hide
C23H32N4O8
 5
1 IC50 = 8.4 nM
2 IC50 = 17 nM
3 Ki = 0.7 nM
4 Ki = 0.76 nM
5 Ki = 6 nM
CP0127391
N-[3-[1-[[(3S)-2-hydroxy-5-oxooxolan-3-yl]carbamoyl]cyclopropyl]-2,4-dioxo-1-propan-2-ylpyrimidin-5-yl]-2-methyl-4-(naphthalen-2-ylamino)benzamide
   Show/Hide
C33H33N5O7
 2
1 IC50 = 9.8 nM
2 IC50 = 160 nM
CP0451099
N-[3-[2-[[(3S)-2-hydroxy-5-oxooxolan-3-yl]amino]-2-oxoethyl]-2,4-dioxo-1-propan-2-ylpyrimidin-5-yl]-4-(naphthalen-2-ylamino)benzamide
   Show/Hide
C30H29N5O7
 1
1 IC50 = 21 nM
CP0111100
N-[3-[1-[[(3S)-2-hydroxy-5-oxooxolan-3-yl]amino]-1-oxopropan-2-yl]-1-methyl-2,4-dioxopyrimidin-5-yl]-4-(quinoxalin-2-ylamino)benzamide
   Show/Hide
C27H25N7O7
 1
1 IC50 = 31.62 nM
Clinical Information about the Protein
Target 1 ( Caspase-1 (CASP1) )
Target Type Clinical trial Target
Disease 1 Target-related Disease  1
1 Rheumatoid arthritis [ICD-11: FA20]
Clinical Trial Drug(s) 1 Clinical Trial Drug  1
1 PRALNACASAN Phase 2
Rheumatoid arthritis